Fractalkine also plays a role in the dissemination of breast cancer cells to bone; and inhibiting the fractalkine receptor, CX3CR1, has been shown to reduce breast cancer cell bone dissemination and development of bone metastatic lesions [134,135]. Here, CX3CR1 is linked to breast carcinoma.